MX2008013827A - Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual. - Google Patents
Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.Info
- Publication number
- MX2008013827A MX2008013827A MX2008013827A MX2008013827A MX2008013827A MX 2008013827 A MX2008013827 A MX 2008013827A MX 2008013827 A MX2008013827 A MX 2008013827A MX 2008013827 A MX2008013827 A MX 2008013827A MX 2008013827 A MX2008013827 A MX 2008013827A
- Authority
- MX
- Mexico
- Prior art keywords
- flibanserin
- post
- treatment
- sexual desire
- desire disorders
- Prior art date
Links
- 208000030047 Sexual desire disease Diseases 0.000 title abstract 2
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002053 flibanserin Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere al uso de flibanserina para la preparación de un medicamento para el tratamiento de trastornos posmenopáusicos del deseo sexual.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74681706P | 2006-05-09 | 2006-05-09 | |
US83098706P | 2006-07-14 | 2006-07-14 | |
PCT/EP2007/054380 WO2007128802A2 (en) | 2006-05-09 | 2007-05-07 | Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008013827A true MX2008013827A (es) | 2008-11-10 |
Family
ID=38566195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008013827A MX2008013827A (es) | 2006-05-09 | 2007-05-07 | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual. |
Country Status (27)
Country | Link |
---|---|
US (4) | US20070265276A1 (es) |
EP (1) | EP2021006B1 (es) |
JP (1) | JP2009536176A (es) |
KR (1) | KR20090005371A (es) |
AR (1) | AR060880A1 (es) |
AU (1) | AU2007247094B2 (es) |
BR (1) | BRPI0712039A2 (es) |
CA (1) | CA2649938A1 (es) |
CL (1) | CL2007001318A1 (es) |
DK (1) | DK2021006T3 (es) |
EA (1) | EA200802208A1 (es) |
EC (1) | ECSP088874A (es) |
ES (1) | ES2551093T3 (es) |
HU (1) | HUE026156T2 (es) |
IL (1) | IL195135A0 (es) |
MX (1) | MX2008013827A (es) |
MY (1) | MY151048A (es) |
NO (1) | NO20084531L (es) |
NZ (1) | NZ573382A (es) |
PE (1) | PE20080090A1 (es) |
PL (1) | PL2021006T3 (es) |
PT (1) | PT2021006E (es) |
RS (1) | RS54398B1 (es) |
SI (1) | SI2021006T1 (es) |
TW (1) | TW200812586A (es) |
UY (1) | UY30333A1 (es) |
WO (1) | WO2007128802A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
EP1858516A1 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions for the treatment and/or prevention of depression |
EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
WO2006125041A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
EP1888071A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of drug-induced sexual dysfunction |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
WO2008000760A1 (en) * | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
JP2009543839A (ja) * | 2006-07-14 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 女性の性的障害を治療するためのフリバンセリンの使用 |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
BRPI0716439B8 (pt) | 2006-08-14 | 2021-05-25 | Boehringer Ingelheim Int | sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos |
BRPI0716436B8 (pt) * | 2006-08-25 | 2021-05-25 | Boehringer Ingelheim Int | sistema de liberação controlada e método para fabricação do mesmo |
WO2008090742A1 (ja) * | 2007-01-23 | 2008-07-31 | National University Corporation Hokkaido University | 眼疾患モデル用非ヒト動物 |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
USD915009S1 (en) | 2018-08-16 | 2021-03-30 | Samsung Electronics Co., Ltd. | Clothing care machine |
USD1017150S1 (en) | 2021-12-28 | 2024-03-05 | Samsung Electronics Co., Ltd. | Clothing care machine |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
US3406178A (en) * | 1964-02-04 | 1968-10-15 | Monsanto Chem Australia Ltd | Preparation of 2-substituted benzimidazoles |
US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
US4200641A (en) * | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
IT1176613B (it) * | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
NL8601494A (nl) * | 1985-06-22 | 1987-01-16 | Sandoz Ag | Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten. |
GB8601160D0 (en) * | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
US5036088A (en) * | 1986-06-09 | 1991-07-30 | Pfizer Inc. | Antiallergy and antiinflammatory agents, compositions and use |
JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
US4954503A (en) * | 1989-09-11 | 1990-09-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(1-substituted-4-piperazinyl)-1H-indazoles |
NZ241613A (en) * | 1991-02-27 | 1993-06-25 | Janssen Pharmaceutica Nv | Highlighting intagliations in tablets |
SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
US5492907A (en) * | 1992-12-09 | 1996-02-20 | The United States Of America As Represented By The Department Of Health & Human Services | Antipsychotic composition and method of treatment |
FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
EP0739488A1 (en) * | 1994-01-14 | 1996-10-30 | Genentech, Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
US6083947A (en) * | 1996-01-29 | 2000-07-04 | The Regents Of The University Of California | Method for treating sexual dysfunctions |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
AU731349B2 (en) * | 1996-12-02 | 2001-03-29 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating sexual dysfunctions |
SG108292A1 (en) * | 1997-06-11 | 2005-01-28 | Procter & Gamble | Film-coated tablet for improved upper gastrointestinal tract safety |
DE69815003T2 (de) * | 1997-09-10 | 2004-04-01 | Takeda Chemical Industries, Ltd. | Stabilisierte pharmazeutische Zusammensetzung |
CH692199A8 (fr) * | 1997-10-09 | 2002-06-14 | Cermol S.A. | Composes pyridiques et compositions pharmaceutique |
JP3724157B2 (ja) * | 1997-10-30 | 2005-12-07 | コニカミノルタホールディングス株式会社 | 映像観察装置 |
FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
US6068846A (en) * | 1998-08-05 | 2000-05-30 | Melaleuca, Incorporated | Methods and materials for treating depression and mood disorder |
EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
US6680071B1 (en) * | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
CN1396829A (zh) * | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
US6586435B2 (en) * | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
US6521623B1 (en) * | 2000-09-19 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
BR0211601A (pt) * | 2001-08-02 | 2004-08-24 | Bidachem Spa | Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US20040132697A1 (en) * | 2002-11-06 | 2004-07-08 | Pfizer Inc. | Treatment of female sexual dysfunction |
WO2004063864A2 (en) * | 2003-01-06 | 2004-07-29 | Laura Berman | Method and system for computerized sexual function assessment of female users |
WO2005007166A1 (en) * | 2003-07-16 | 2005-01-27 | Pfizer Limited | Treatment of sexual dysfunction |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
MXPA06012059A (es) * | 2004-04-22 | 2007-01-25 | Boehringer Ingelheim Int | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii. |
US20060014757A1 (en) * | 2004-07-14 | 2006-01-19 | Boehringer Ingelheim Pharmaceuticals | Method for the treatment of anorexia nervosa |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
EP1858516A1 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions for the treatment and/or prevention of depression |
WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
EP1888071A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of drug-induced sexual dysfunction |
WO2006125041A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
US8227476B2 (en) * | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
WO2007048803A1 (en) * | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
CA2641917A1 (en) * | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
JP2009527525A (ja) * | 2006-02-20 | 2009-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁治療用のベンゾイミダゾロン誘導体 |
EP1991228A1 (en) * | 2006-02-28 | 2008-11-19 | Boehringer Ingelheim International GmbH | Treatment of prevention of valvular heart disease with flibanserin |
WO2008000760A1 (en) * | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
JP2009543839A (ja) * | 2006-07-14 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 女性の性的障害を治療するためのフリバンセリンの使用 |
JP2009543767A (ja) * | 2006-07-14 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンとカフェインとを含む組成物、その調製方法及び薬剤としての使用 |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
BRPI0716439B8 (pt) * | 2006-08-14 | 2021-05-25 | Boehringer Ingelheim Int | sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos |
BRPI0716436B8 (pt) * | 2006-08-25 | 2021-05-25 | Boehringer Ingelheim Int | sistema de liberação controlada e método para fabricação do mesmo |
-
2007
- 2007-05-07 HU HUE07728833A patent/HUE026156T2/en unknown
- 2007-05-07 MX MX2008013827A patent/MX2008013827A/es not_active Application Discontinuation
- 2007-05-07 EP EP07728833.0A patent/EP2021006B1/en active Active
- 2007-05-07 NZ NZ573382A patent/NZ573382A/en not_active IP Right Cessation
- 2007-05-07 SI SI200731692T patent/SI2021006T1/sl unknown
- 2007-05-07 DK DK07728833.0T patent/DK2021006T3/en active
- 2007-05-07 KR KR1020087027420A patent/KR20090005371A/ko not_active Application Discontinuation
- 2007-05-07 BR BRPI0712039-7A patent/BRPI0712039A2/pt not_active Application Discontinuation
- 2007-05-07 WO PCT/EP2007/054380 patent/WO2007128802A2/en active Application Filing
- 2007-05-07 CA CA002649938A patent/CA2649938A1/en not_active Abandoned
- 2007-05-07 PE PE2007000551A patent/PE20080090A1/es not_active Application Discontinuation
- 2007-05-07 ES ES07728833.0T patent/ES2551093T3/es active Active
- 2007-05-07 EA EA200802208A patent/EA200802208A1/ru unknown
- 2007-05-07 PL PL07728833T patent/PL2021006T3/pl unknown
- 2007-05-07 RS RS20150713A patent/RS54398B1/en unknown
- 2007-05-07 MY MYPI20084432 patent/MY151048A/en unknown
- 2007-05-07 PT PT77288330T patent/PT2021006E/pt unknown
- 2007-05-07 AU AU2007247094A patent/AU2007247094B2/en not_active Ceased
- 2007-05-07 JP JP2009508365A patent/JP2009536176A/ja active Pending
- 2007-05-08 CL CL2007001318A patent/CL2007001318A1/es unknown
- 2007-05-08 US US11/745,515 patent/US20070265276A1/en not_active Abandoned
- 2007-05-08 TW TW096116300A patent/TW200812586A/zh unknown
- 2007-05-08 UY UY30333A patent/UY30333A1/es not_active Application Discontinuation
- 2007-05-09 AR ARP070102001A patent/AR060880A1/es unknown
-
2008
- 2008-10-28 NO NO20084531A patent/NO20084531L/no not_active Application Discontinuation
- 2008-11-06 IL IL195135A patent/IL195135A0/en unknown
- 2008-11-07 EC EC2008008874A patent/ECSP088874A/es unknown
-
2012
- 2012-11-12 US US13/674,486 patent/US20130190326A1/en not_active Abandoned
-
2014
- 2014-06-24 US US14/313,291 patent/US20150051221A1/en not_active Abandoned
-
2015
- 2015-05-01 US US14/702,125 patent/US20150374683A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150051221A1 (en) | 2015-02-19 |
AU2007247094A1 (en) | 2007-11-15 |
NO20084531L (no) | 2008-12-02 |
US20070265276A1 (en) | 2007-11-15 |
MY151048A (en) | 2014-03-31 |
BRPI0712039A2 (pt) | 2011-12-20 |
IL195135A0 (en) | 2009-09-22 |
US20130190326A1 (en) | 2013-07-25 |
CL2007001318A1 (es) | 2008-01-18 |
HUE026156T2 (en) | 2016-06-28 |
PE20080090A1 (es) | 2008-03-14 |
EP2021006A2 (en) | 2009-02-11 |
EA200802208A1 (ru) | 2009-04-28 |
US20150374683A1 (en) | 2015-12-31 |
ECSP088874A (es) | 2008-12-30 |
PL2021006T3 (pl) | 2015-12-31 |
AR060880A1 (es) | 2008-07-16 |
KR20090005371A (ko) | 2009-01-13 |
UY30333A1 (es) | 2008-01-02 |
CA2649938A1 (en) | 2007-11-15 |
WO2007128802A3 (en) | 2008-06-12 |
EP2021006B1 (en) | 2015-08-12 |
SI2021006T1 (sl) | 2016-01-29 |
ES2551093T3 (es) | 2015-11-16 |
NZ573382A (en) | 2012-02-24 |
DK2021006T3 (en) | 2015-11-23 |
WO2007128802A2 (en) | 2007-11-15 |
TW200812586A (en) | 2008-03-16 |
JP2009536176A (ja) | 2009-10-08 |
PT2021006E (pt) | 2015-11-12 |
AU2007247094B2 (en) | 2012-11-01 |
RS54398B1 (en) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY151048A (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
MY145439A (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
IL178730A0 (en) | New pharmaceutical compositions for the treatment of sexual disorders ii | |
MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
EP2166837A4 (en) | DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS | |
MY152279A (en) | Immediate release pharmaceutical compositions comprising oxycodone and naloxone | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
IL196745A (en) | Idabanon for use in providing mucosal pathways to treat disease | |
MX2010002032A (es) | Uso de flibanserina para el tratamiento de sintomas vasomotores. | |
IL198202A0 (en) | Peptide-cytotoxic conjugates | |
UA97950C2 (ru) | Применение флибансерина для лечения расстройств полового влечения в постклимактерический период | |
PL2036575T3 (pl) | Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością | |
SG153698A1 (en) | Composition and method for prevention and treatment of alzheimeræs disease | |
UA96278C2 (ru) | Применение флибансерина для лечения расстройств полового влечения в предклимактерический период | |
EP2220057A4 (en) | PROSTAGLANDIN E1 AND E2 ANALOGUES FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | |
MY148092A (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease | |
WO2008061966A3 (en) | New use of flibanserin | |
ZA200607463B (en) | New pharmaceutical compositions for the treatment of sexual disorders II | |
TW200738229A (en) | Memantine for the normalization of visual acuity deficits | |
UA89921C2 (ru) | Способ лечения хронического обструктивного заболевания лёгких при помощи месалазина | |
NZ623275A (en) | Treatment of ocular disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |